Skip to main content

epoetin theta (Eporatio®)

 

Status: Partially superseded

AWMSG ADVICE PARTIALLY SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2014. Refer to TA323:  Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. 

Epoetin theta (Eporatio®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with symptomatic anaemia associated with chronic renal failure.

 Final Recommendation: epoetin theta (Eporatio) 592 (PDF, 358Kb)

Medicine details

Medicine name epoetin theta (Eporatio®)
Formulation solution for injection
Reference number 592
Indication

Treatment of adult patients with symptomatic anaemia associated with chronic renal failure or those with non-myeloid malignancies receiving chemotherapy

Company TEVA UK Ltd
BNF chapter Nutrition & blood
Submission type Full
Status Partially superseded
Advice number 1610
NMG meeting date 15/09/2010
AWMSG meeting date 13/10/2010
Ratification by Welsh Government 17/11/2010
Date of issue 18/11/2010
NICE guidance

TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (external website - opens in new window)

 

 

Follow AWTTC: